Form 4: Immunome CTO Philip Tsai Receives Significant Stock Option Grant

Immunome Inc.'s Chief Technical Officer, Philip Tsai, was granted 190,000 employee stock options with an exercise price of $10.60, aligning executive incentives with shareholder value.

Summary

• Philip Tsai, Immunome Inc.'s Chief Technical Officer, was granted 190,000 employee stock options.
• The options have an exercise price of $10.60 per share.
• The grant date for these options was July 29, 2025.
• The options will begin vesting on July 29, 2026, with 25% of the shares vesting on that date.
• Following the initial vesting, one-thirty-sixth (1/36th) of the remaining shares will vest every month thereafter.
• The options are set to expire on July 28, 2035.

Sentiment

Score: 7

Explanation: The filing indicates a routine executive compensation event, aligning management incentives with shareholder interests, which is generally positive for corporate governance and long-term strategy.

Positives

• The grant of 190,000 employee stock options to the Chief Technical Officer, Philip Tsai, aligns management's long-term interests with shareholder value.
• Stock options are a common and effective tool for executive retention and motivation.

Negatives

• Potential for future share dilution if the options are exercised, although this is a standard aspect of equity compensation.

Future Outlook

The vesting schedule indicates a long-term commitment for the Chief Technical Officer, with options vesting over several years, aligning future performance with equity incentives.

Industry Context

The grant of stock options to a key executive like the Chief Technical Officer is a standard practice within the biotechnology and pharmaceutical industries, used to attract, retain, and incentivize top talent by linking their compensation to the company's long-term performance.

Comparison to Industry Standards

• Executive stock option grants are a widely adopted compensation strategy across various industries, including biotech, to align management incentives with shareholder returns.
• While the specific size of this grant (190,000 options) would typically be benchmarked against grants to similar roles in companies of comparable market capitalization and stage of development, this filing alone does not provide sufficient data for a detailed comparative analysis against specific companies or projects.
• The structure, including a multi-year vesting schedule and a defined exercise price, is consistent with common industry practices for equity-based compensation.

Related Party Transactions

• The grant of employee stock options to Philip Tsai, a Chief Technical Officer, constitutes a related party transaction as it involves compensation to a key executive.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also benefits from increased executive alignment and motivation.
• Employees: Reflects a standard compensation practice that can attract and retain talent within the company.
• Executive (Philip Tsai): Directly benefits from the potential for significant equity upside, contingent on company performance and stock price appreciation.

Next Steps

• The options will begin vesting on July 29, 2026, with 25% of the shares.
• Monthly vesting of 1/36th of the remaining shares will occur thereafter.

Key Dates

Recommendation

The filing details a routine stock option grant to a key executive, which is a standard compensation practice and does not provide sufficient new information to alter an investment thesis based solely on this report.

Keywords

Immunome, IMNM, Philip Tsai, Stock Option, CTO, Insider Transaction, Form 4, Equity Compensation, Executive Compensation